Algeta demonstrates radioimmunotherapeutic potential of a tumor-targeting monoclonal antibody labeled with Thorium-227
Advertisement
Algeta ASA announced the publication of its study demonstrating the potential of monoclonal antibodies (mAbs) labeled with alpha-emitting radionuclides for the targeting and treatment of cancer. Through the application of Algeta's proprietary TH-1 Therapeutic Antibody Enhancement technology, it has been shown that in vivo a Thorium-227 conjugate of the chimeric mAb rituximab retains immunoreactivity against human CD20-positive cells and its biodistribution properties are compatible with therapeutic mAbs developed for oncology indications.
While these initial observations have been made with a mAb already indicated for relapsed or refractory non-Hodgkin's lymphoma, Algeta anticipates this study having broader implications for mAb-alpha emitter conjugates in a therapeutic setting. In particular, given the known affinity of selected alpha-emitting nuclides for skeletal tissues to which a number of solid tumors metastasize, mAb-directed approaches would appear to have therapeutic potential even in advanced stages of cancer.
In view of these results, Algeta is now seeking partner companies committed to the development and commercialization of alpha-particle emitting mAbs as products for the treatment of primary and advanced cancer conditions.
Original publication: J. Dahle et al.; Nuclear Medicine and Biology 2006, 33, 271-279.
Other news from the department research and development
Most read news
More news from our other portals
See the theme worlds for related content
Topic world Antibodies
Antibodies are specialized molecules of our immune system that can specifically recognize and neutralize pathogens or foreign substances. Antibody research in biotech and pharma has recognized this natural defense potential and is working intensively to make it therapeutically useful. From monoclonal antibodies used against cancer or autoimmune diseases to antibody-drug conjugates that specifically transport drugs to disease cells - the possibilities are enormous
Topic world Antibodies
Antibodies are specialized molecules of our immune system that can specifically recognize and neutralize pathogens or foreign substances. Antibody research in biotech and pharma has recognized this natural defense potential and is working intensively to make it therapeutically useful. From monoclonal antibodies used against cancer or autoimmune diseases to antibody-drug conjugates that specifically transport drugs to disease cells - the possibilities are enormous
Last viewed contents
Genzyme and Project HOPE Partner to Rebuild Critical Health Care Programs in Tsunami-Affected Areas
ThromboGenics and BioInvent Complete Patient Recruitment of Phase II DVT Prophylaxis Study with Anti-Factor VIII (TB-402)
Evotec expands Oxfordshire site into a fully-integrated R&D centre - "Dorothy Crowfoot Hodgkin Campus"
From cancer medication to antibiotic - Modified cancer drug effective against multi-resistant bacteria
Lyme disease: Probability of developing the disease is genetically predisposed - Research team discovers gene variant and genes involved in immune regulation that are responsible for the outbreak of Lyme disease
Sarcospan, a little protein for a big problem
Insects as mini molecule-making factories, marking a breakthrough in chemical engineering - Caterpillar factories produce fluorescent nanocarbons
Key molecular interactions of the ZMapp anti-Ebola virus cocktail identified
Strüngmann Award Honors Araris Biotech Founding Team as 2025 Winner - The founding team is developing a breakthrough technology to establish a new generation of targeted cancer therapies
Upcoming ECHA notification deadlines
Caprotec bioanalytics appoints Prof. Dr. Metternich as Managing Director, Chief Business Officer and Chief Operating Officer
